Effectiveness of ustekinumab dose escalation in Crohn’s disease patients with insufficient response to standard‐dose subcutaneous maintenance therapyUri Kopylov, David Drobne, Davide De Marco et al.|Alimentary Pharmacology & Therapeutics|2020Cited by 80
Safety and efficacy of combining biologics or small molecules for inflammatory bowel disease or immune‐mediated inflammatory diseases: A European retrospective observational studyLaurent Goessens, Jean‐Frédéric Colombel, An Outtier et al.|United European Gastroenterology Journal|2021Cited by 71